Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia

Abstract Evinacumab, an angiopoietin‐like protein 3 (ANGPTL3) inhibitor, has been shown to significantly reduce low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). This work characterized the population pharmacokinetics (PK)/pharmacodynamics...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Xia Pu, Mark Sale, Feng Yang, Yi Zhang, John D. Davis, Nidal Al‐Huniti
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Wiley 2021-11-01
Saila:	CPT: Pharmacometrics & Systems Pharmacology
Sarrera elektronikoa:	https://doi.org/10.1002/psp4.12711
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!